Wide Ranks

ACLX

Arcellx, Inc.

89.07

Top Statistics
Market Cap 4 B Forward PE -39.86 Revenue Growth 74.00 %
Current Ratio 4.29 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -25.94 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -65.97 Enterprise / Revenue 27.64 Price To Sales Trailing12 Months 30.91
Profitability
Profit Margins -25.94 % Operating Margins -129.14 %
Balance Sheet
Total Cash 574 M Total Cash Per Share 10.62 Total Debt 65 M
Total Debt To Equity 13.53 Current Ratio 4.29 Book Value Per Share 8.95
All Measures
Short Ratio 667.00 % Message Board Id finmb_312283010 Shares Short Prior Month 4 M
Return On Equity -0.1079 City Redwood City Uuid 8ab0f618-4d1b-3236-9d77-b2652bd27005
Previous Close 90.96 First Trade Date Epoch Utc 1 B Book Value 8.95
Beta 0.2650 Total Debt 65 M Volume 319521
Price To Book 9.96 Fifty Two Week Low 46.42 Total Cash Per Share 10.62
Total Revenue 155 M Shares Short Previous Month Date 1 B Target Median Price 114.00
Audit Risk 9 Max Age 86400 Recommendation Mean 1.32
Sand P52 Week Change 0.3133 Operating Margins -129.14 % Target Mean Price 111.81
Net Income To Common -40423000 Short Percent Of Float 0.0943 Implied Shares Outstanding 54 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 462370
Average Volume10days 462370 Total Cash 574 M Next Fiscal Year End 1 B
Revenue Per Share 2.98 Held Percent Insiders 0.1262 Ebitda Margins -41.91 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 90.96 Target Low Price 73.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 87.97 Open 91.44
Free Cashflow 37 M State CA Dividend Yield 0.00 %
Return On Assets -0.0629 Time Zone Short Name EST Board Risk 9
Trailing Eps -0.7100 Day Low 88.51 Address1 800 Bridge Parkway
Shares Outstanding 54 M Compensation Risk 10 Price Hint 2
Target High Price 134.00 Website https://www.arcellx.com 52 Week Change 0.6956
Average Volume 545137 Forward Eps -2.25 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 421.60 % Is_sp_500 False
Regular Market Day High 92.92 Profit Margins -25.94 % Debt To Equity 13.53
Fifty Two Week High 107.37 Day High 92.92 Shares Short 4 M
Regular Market Open 91.44 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 27.64 Revenue Growth 74.00 % Shares Percent Shares Out 0.0823
Operating Cashflow 20 M Currency USD Time Zone Full Name America/New_York
Market Cap 4 B Is_nasdaq_100 False Zip 94065
Quote Type EQUITY Industry Biotechnology Long Name Arcellx, Inc.
Overall Risk 10 Regular Market Day Low 88.51 Held Percent Institutions 0.9493
Current Price 89.07 Enterprise To Ebitda -65.97 Financial Currency USD
Current Ratio 4.29 Gross Margins 95.26 % Industry Disp Biotechnology
Number Of Analyst Opinions 16 Country United States Float Shares 35 M
Two Hundred Day Average 67.55 Governance Epoch Date 1 B Enterprise Value 4 B
Price To Sales Trailing12 Months 30.91 Forward PE -39.86 Regular Market Volume 319521
Ebitda -65299000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.

The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS.

Further, it focuses on the development of product candidates for solid tumor programs.

It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel.

The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.

Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.